首页> 美国卫生研究院文献>Theranostics >Tumor acidity activated triphenylphosphonium-based mitochondrial targeting nanocarriers for overcoming drug resistance of cancer therapy
【2h】

Tumor acidity activated triphenylphosphonium-based mitochondrial targeting nanocarriers for overcoming drug resistance of cancer therapy

机译:肿瘤酸性激活的基于三苯基-的线粒体靶向纳米载体可克服癌症治疗的耐药性

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The drug resistance in cancer treatment with DOX is mainly related to the overexpression of drug efflux proteins, residing in the plasma and nuclear membranes. Delivering DOX into the mitochondria, lacking drug efflux proteins, is an interesting method to overcome DOX resistance. To solve the problem of positively charged triphenylphosphonium (TPP) for mitochondrial targeting in vivo, a charge reversal strategy was developed.>Methods: An acidity triggered cleavable polyanion PEI-DMMA (PD) was coated on the surface of positively charged lipid-polymer hybrid nanoparticle (DOX-PLGA/CPT) to form DOX-PLGA/CPT/PD via electrostatic interaction. The mitochondrial localization and anticancer efficacy of DOX-PLGA/CPT/PD was evaluated both in vitro and in vivo.>Results: The surface negative charge of DOX-PLGA/CPT/PD prevents from rapid clearance in the blood and improved the accumulation in tumor tissue through the enhanced permeability and retention (EPR) effect. The hydrolysis of amide bonds in PD in weakly acidic tumor tissue leads to the conversion of DOX-PLGA/CPT/PD to DOX-PLGA/CPT. The positive charge of DOX-PLGA/CPT enhances the interaction with tumor cells, promotes the uptake and improves DOX contents in tumor cells. Once endocytosed by tumor cells, the exposed TPP in nanomedicine results in effective mitochondrial localization of DOX-PLGA/CPT. Afterward, DOX can release from the nanomedicine in the mitochondria, target mtDNA, induce tumor cells apoptosis and overcome DOX resistance of MCF-7/ADR breast cancer.>Conclusion: Tumor acidity triggered charge reversal of TPP-containing nanomedicine and activation of mitochondrial targeting is a simple and effective strategy for the delivery of DOX into the mitochondria of cancer cells and overcoming DOX resistance of MCF-7/ADR tumor both in vitro and in vivo, providing new insight in the design of nanomedicines for cancer chemotherapy.
机译:用DOX进行癌症治疗时的耐药性主要与存在于质膜和核膜中的药物外排蛋白的过表达有关。将缺乏药物外排蛋白的线粒体传递到线粒体中,是克服线粒体抗药性的一种有趣方法。为了解决体内线粒体靶向带正电荷的三苯基phosph(TPP)的问题,开发了一种电荷逆转策略。>方法:将酸度触发的可裂解聚阴离子PEI-DMMA(PD)涂覆在表面带正电荷的脂质-聚合物杂化纳米颗粒(DOX-PLGA / CPT)通过静电相互作用形成DOX-PLGA / CPT / PD。分别在体内和体外评估了DOX-PLGA / CPT / PD的线粒体定位和抗癌效果。>结果:DOX-PLGA / CPT / PD的表面负电荷阻止了其在体内的快速清除。通过增强的通透性和保留(EPR)效果改善血液和肿瘤组织中的蓄积。弱酸性肿瘤组织中PD中酰胺键的水解导致DOX-PLGA / CPT / PD转化为DOX-PLGA / CPT。 DOX-PLGA / CPT的正电荷增强与肿瘤细胞的相互作用,促进摄取并改善肿瘤细胞中的DOX含量。一旦被肿瘤细胞内吞,纳米药物中暴露的TPP会导致DOX-PLGA / CPT的有效线粒体定位。之后,DOX可以从线粒体中的纳米药物中释放出来,靶向mtDNA,诱导肿瘤细胞凋亡并克服MCF-7 / ADR乳腺癌的DOX耐药性。>结论:肿瘤的酸性触发了含TPP的电荷逆转纳米药物和线粒体靶向激活是一种简单有效的策略,可将DOX递送至癌细胞的线粒体并在体外和体内克服MCF-7 / ADR肿瘤的DOX耐药性,为纳米药物的设计提供了新见识癌症化疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号